An open-label multicenter study to assess the efficacy and safety of daily oral administration of 5 and 10mg VESIcare (solifenacin succinate) in patients who wish to switch from Detrol LA (tolterodine tartrate extended release) for the treatment of overactive bladder symptoms versus: VESIcare efficacy and research study US
Latest Information Update: 04 Nov 2014
Price :
$35 *
At a glance
- Drugs Solifenacin (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Acronyms VERSUS
- Sponsors Astellas Pharma
- 12 Jun 2007 New trial record.